184 related articles for article (PubMed ID: 7680698)
21. The effect of mutations in the MHC class I peptide binding groove on the cytotoxic T lymphocyte recognition of the Kb-restricted ovalbumin determinant.
Nikolić-Zugić J; Carbone FR
Eur J Immunol; 1990 Nov; 20(11):2431-7. PubMed ID: 2253683
[TBL] [Abstract][Full Text] [Related]
22. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.
Porgador A; Gilboa E
J Exp Med; 1995 Jul; 182(1):255-60. PubMed ID: 7540653
[TBL] [Abstract][Full Text] [Related]
23. Delivery by Trypanosoma cruzi of proteins into the MHC class I antigen processing and presentation pathway.
Garg N; Nunes MP; Tarleton RL
J Immunol; 1997 Apr; 158(7):3293-302. PubMed ID: 9120286
[TBL] [Abstract][Full Text] [Related]
24. Modifying Antigen-Encapsulating Liposomes with KALA Facilitates MHC Class I Antigen Presentation and Enhances Anti-tumor Effects.
Miura N; Akita H; Tateshita N; Nakamura T; Harashima H
Mol Ther; 2017 Apr; 25(4):1003-1013. PubMed ID: 28236573
[TBL] [Abstract][Full Text] [Related]
25. Accessory cell requirements for saponin adjuvant-induced class I MHC antigen-restricted cytotoxic T-lymphocytes.
Wu JY; Gardner BH; Kushner NN; Pozzi LA; Kensil CR; Cloutier PA; Coughlin RT; Newman MJ
Cell Immunol; 1994 Apr; 154(1):393-406. PubMed ID: 7907530
[TBL] [Abstract][Full Text] [Related]
26. Presentation of exogenous antigen with class I major histocompatibility complex molecules.
Rock KL; Gamble S; Rothstein L
Science; 1990 Aug; 249(4971):918-21. PubMed ID: 2392683
[TBL] [Abstract][Full Text] [Related]
27. Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization.
Carbone FR; Bevan MJ
J Exp Med; 1989 Mar; 169(3):603-12. PubMed ID: 2784478
[TBL] [Abstract][Full Text] [Related]
28. Peptide affinity for MHC influences the phenotype of CD8(+) T cells primed in vivo.
Ma H; Kapp JA
Cell Immunol; 2001 Nov; 214(1):89-96. PubMed ID: 11902833
[TBL] [Abstract][Full Text] [Related]
29. Auranofin, an immunosuppressive drug, inhibits MHC class I and MHC class II pathways of antigen presentation in dendritic cells.
Han S; Kim K; Song Y; Kim H; Kwon J; Lee YH; Lee CK; Lee SJ; Ha N; Kim K
Arch Pharm Res; 2008 Mar; 31(3):370-6. PubMed ID: 18409052
[TBL] [Abstract][Full Text] [Related]
30. The role of macrophages in the induction and regulation of immunity elicited by exogenous antigens.
Wijburg OL; van den Dobbelsteen GP; Vadolas J; Sanders A; Strugnell RA; van Rooijen N
Eur J Immunol; 1998 Feb; 28(2):479-87. PubMed ID: 9521056
[TBL] [Abstract][Full Text] [Related]
31. Sensitization of MHC class I-restricted T cells to exogenous proteins: evidence for an alternative class I-restricted antigen presentation pathway.
Martinez-Kinader B; Lipford GB; Wagner H; Heeg K
Immunology; 1995 Oct; 86(2):287-95. PubMed ID: 7490131
[TBL] [Abstract][Full Text] [Related]
32. An improved method of loading pH-sensitive liposomes with soluble proteins for class I restricted antigen presentation.
Zhou F; Rouse BT; Huang L
J Immunol Methods; 1991 Dec; 145(1-2):143-52. PubMed ID: 1765645
[TBL] [Abstract][Full Text] [Related]
33. Generation of antigen specific CD8+ cytotoxic T cells following immunization with soluble protein formulated with novel glycoside adjuvants.
Sheikh NA; Rajananthanan P; Attard GS; Morrow WJ
Vaccine; 1999 Aug; 17(23-24):2974-82. PubMed ID: 10462232
[TBL] [Abstract][Full Text] [Related]
34. Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides.
Carbone FR; Moore MW; Sheil JM; Bevan MJ
J Exp Med; 1988 Jun; 167(6):1767-79. PubMed ID: 2455012
[TBL] [Abstract][Full Text] [Related]
35. Epitope cleavage by Leishmania endopeptidase(s) limits the efficiency of the exogenous pathway of major histocompatibility complex class I-associated antigen presentation.
Garcia MR; Graham S; Harris RA; Beverley SM; Kaye PM
Eur J Immunol; 1997 Apr; 27(4):1005-13. PubMed ID: 9130657
[TBL] [Abstract][Full Text] [Related]
36. MHC class I-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived dendritic cells.
Utsugi-Kobukai S; Fujimaki H; Hotta C; Nakazawa M; Minami M
Immunol Lett; 2003 Oct; 89(2-3):125-31. PubMed ID: 14556969
[TBL] [Abstract][Full Text] [Related]
37. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway.
Rock KL; Clark K
J Immunol; 1996 May; 156(10):3721-6. PubMed ID: 8621907
[TBL] [Abstract][Full Text] [Related]
38. Vaccination of class I major histocompatibility complex (MHC)-restricted murine CD8+ cytotoxic T lymphocytes towards soluble antigens: immunostimulating-ovalbumin complexes enter the class I MHC-restricted antigen pathway and allow sensitization against the immunodominant peptide.
Heeg K; Kuon W; Wagner H
Eur J Immunol; 1991 Jun; 21(6):1523-7. PubMed ID: 1904363
[TBL] [Abstract][Full Text] [Related]
39. Manifestation of the MHC-unrestricted killing potential of a cytotoxic T cell clone requires activation in response to MHC-restricted self-presentation of antigen.
Dick T; Staege MS; Reichmann G; Reske-Kunz AB
J Immunol; 1993 Apr; 150(7):2575-83. PubMed ID: 8454844
[TBL] [Abstract][Full Text] [Related]
40. Delivery of protein antigen to the major histocompatibility complex class I-restricted antigen presentation pathway.
Zhou F; Huang L
J Drug Target; 1995; 3(2):91-109. PubMed ID: 7496732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
